SCHEMBL1716910

SCHEMBL1716910

CCOC(=O)[C@H]1CN(Cc2ccccc2)C[C@@H]1CC

nearest known ligand 0.59

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.54
ALDH1A1 P00352 3/20 0.52
L3MBTL1 Q9Y468 2/20 0.50
ATM Q13315 1/20 0.50
SIGMAR1 Q99720 2/20 0.47
MAPK1 P28482 2/20 0.46
LMNA P02545 1/20 0.46
CCR8 P51685 1/20 0.46
KDM4E B2RXH2 2/20 0.46
PKM P14618 1/20 0.45
S1PR5 Q9H228 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14791215 1.00 USP30 (0.54) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL20848234 1.00 USP30 (0.54) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL14791216 1.00 USP30 (0.54) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL1716911 1.00 USP30 (0.54) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL6679071 1.00 USP30 (0.54) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL1055082 0.90 USP30 (0.62) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL14037432 0.90 USP30 (0.62) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL853539 0.90 USP30 (0.62) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL853540 0.90 USP30 (0.62) USP30ALDH1A1L3MBTL1ATMSIGMAR1
SCHEMBL13177349 0.90 USP30 (0.62) USP30ALDH1A1L3MBTL1ATMSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587424-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS Bridgene Biosciences, Inc. (US) 2025-07-23 EP disclosed
CN-119894866-A YAP/TAZ-TEAD oncoprotein inhibitors 布里奇恩生物科学公司 2025-04-25 CN disclosed
WO-2024059317-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS BRIDGENE BIOSCIENCES, INC. (US) 2024-03-21 WO disclosed
WO-2024059317-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS BRIDGENE BIOSCIENCES, INC. (US) 2024-03-21 WO disclosed
WO-2019057103-A1 JAK INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION IN THE FIELD OF MEDICINE 上海华汇拓医药科技有限公司 2019-03-28 WO disclosed
EP-2152712-B1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER (US) 2012-01-11 EP disclosed
US-7964607-B2 Pyrazolo[3,4-d]pyrimidine compounds PFIZER INC. (US) 2011-06-21 US disclosed
EP-2152712-A1 AMINO-HETEROCYCLIC COMPOUNDS Pfizer Inc. (US) 2010-02-17 EP disclosed
US-20090030003-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC 2009-01-29 US disclosed
WO-2008139293-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 2008-11-20 WO disclosed
EP-1112253-B1 BRANCHED ALKYL PYRROLIDINE-3-CARBOXYLIC ACIDS WARNER LAMBERT CO (US) 2004-10-20 EP disclosed
US-6245801-B1 ANTIEPILEPIC AGENTS; BRAIN DISORDERS; PSYCHOLOGICLA DISORDERS WARNER-LAMBERT COMPANY 2001-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030003-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A USP30 1641/4885ALDH1A1 770/4885L3MBTL1 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.